These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27324431)

  • 1. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.
    Hewer S; Varley S; Boxer AL; Paul E; Williams DR;
    Mov Disord; 2016 Oct; 31(10):1574-1577. PubMed ID: 27324431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.
    Bang J; Lobach IV; Lang AE; Grossman M; Knopman DS; Miller BL; Schneider LS; Doody RS; Lees A; Gold M; Morimoto BH; Boxer AL;
    Parkinsonism Relat Disord; 2016 Jul; 28():41-48. PubMed ID: 27172829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.
    Tsai RM; Lobach I; Bang J; Whitwell JL; Senjem ML; Jack CR; Rosen H; Miller B; Boxer AL;
    Parkinsonism Relat Disord; 2016 Jul; 28():29-35. PubMed ID: 27132501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy.
    Abate F; Russo M; Ricciardi C; Tepedino MF; Romano M; Erro R; Pellecchia MT; Amboni M; Barone P; Picillo M
    Parkinsonism Relat Disord; 2023 Apr; 109():105345. PubMed ID: 36868037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroinflammation predicts disease progression in progressive supranuclear palsy.
    Malpetti M; Passamonti L; Jones PS; Street D; Rittman T; Fryer TD; Hong YT; Vàsquez Rodriguez P; Bevan-Jones WR; Aigbirhio FI; O'Brien JT; Rowe JB
    J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):769-775. PubMed ID: 33731439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments.
    Wills AM; Pantelyat A; Espay A; Chan J; Litvan I; Xie T; Dale ML; Gunzler SA; Tartaglia MC; Fox SH; Rodriguez-Porcel F; Sharma M; Lang AE; Boxer AL; ; Golbe LI
    Mov Disord; 2022 Jun; 37(6):1265-1271. PubMed ID: 35363932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical rating scale for progressive supranuclear palsy.
    Golbe LI; Ohman-Strickland PA
    Brain; 2007 Jun; 130(Pt 6):1552-65. PubMed ID: 17405767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
    Boxer AL; Lang AE; Grossman M; Knopman DS; Miller BL; Schneider LS; Doody RS; Lees A; Golbe LI; Williams DR; Corvol JC; Ludolph A; Burn D; Lorenzl S; Litvan I; Roberson ED; Höglinger GU; Koestler M; Jack CR; Van Deerlin V; Randolph C; Lobach IV; Heuer HW; Gozes I; Parker L; Whitaker S; Hirman J; Stewart AJ; Gold M; Morimoto BH;
    Lancet Neurol; 2014 Jul; 13(7):676-85. PubMed ID: 24873720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.
    Stamelou M; Schöpe J; Wagenpfeil S; Del Ser T; Bang J; Lobach IY; Luong P; Respondek G; Oertel WH; Boxer A; Höglinger GU;
    Mov Disord; 2016 May; 31(5):742-7. PubMed ID: 26948290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy.
    Leclair-Visonneau L; Rouaud T; Debilly B; Durif F; Houeto JL; Kreisler A; Defebvre L; Lamy E; Volteau C; Nguyen JM; Dily SL; Damier P; Boutoleau-Bretonnière C; Lejeune P; Derkinderen P
    Clin Neurol Neurosurg; 2016 Jul; 146():35-9. PubMed ID: 27136096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Modified Progressive Supranuclear Palsy Rating Scale.
    Grötsch MT; Respondek G; Colosimo C; Compta Y; Corvol JC; Ferreira J; Huber MK; Klietz M; Krey LFM; Levin J; Jecmenica-Lukic M; Macías-García D; Meissner WG; Mir P; Morris H; Nilsson C; Rowe JB; Seppi K; Stamelou M; van Swieten JC; Wenning G; Del Ser T; Golbe LI; Höglinger GU;
    Mov Disord; 2021 May; 36(5):1203-1215. PubMed ID: 33513292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome.
    Xie T; Wills AM; Liao C; Dale ML; Ramsden DB; Padmanaban M; Abou Chaar W; Pantelyat A; Golbe LI
    Mov Disord; 2023 Feb; 38(2):304-312. PubMed ID: 36573662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol: A valuable tool for evaluating progressive supranuclear palsy.
    Weng R; Wei X; Yu B; Zhu S; Yang X; Xie F; Zhang M; Jiang Y; Feng ZP; Sun HS; Xia Y; Jin K; Chan P; Wang Q; Gao X
    Parkinsonism Relat Disord; 2018 Jul; 52():37-42. PubMed ID: 29574085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants.
    Street D; Malpetti M; Rittman T; Ghosh BCP; Murley AG; Coyle-Gilchrist I; Passamonti L; Rowe JB
    Brain Commun; 2021; 3(3):fcab206. PubMed ID: 34541533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Progressive Supranuclear Palsy Clinical Deficits Scale.
    Piot I; Schweyer K; Respondek G; Stamelou M; ; ; ; Sckopke P; Schenk T; Goetz CG; Stebbins GT; Höglinger GU
    Mov Disord; 2020 Apr; 35(4):650-661. PubMed ID: 31951049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rehabilitation in progressive supranuclear palsy: Effectiveness of two multidisciplinary treatments.
    Clerici I; Ferrazzoli D; Maestri R; Bossio F; Zivi I; Canesi M; Pezzoli G; Frazzitta G
    PLoS One; 2017; 12(2):e0170927. PubMed ID: 28158197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
    VandeVrede L; Dale ML; Fields S; Frank M; Hare E; Heuer HW; Keith K; Koestler M; Ljubenkov PA; McDermott D; Ohanesian N; Richards J; Rojas JC; Thijssen EH; Walsh C; Wang P; Wolf A; Quinn JF; Tsai R; Boxer AL
    Mov Disord Clin Pract; 2020 May; 7(4):440-447. PubMed ID: 32373661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Convenient Prognostic Tool and Staging System for Progressive Supranuclear Palsy.
    Golbe LI; Ohman-Strickland P; Beisser EB; Elghoul FT
    Mov Disord Clin Pract; 2020 Aug; 7(6):664-671. PubMed ID: 32775512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale.
    Pantelyat A; Higginbotham L; Rosenthal L; Lanham D; Nesspor V; AlSalihi M; Bang J; Wang J; Albert M
    Neurodegener Dis; 2020; 20(4):139-146. PubMed ID: 33789283
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Liu FT; Lu JY; Li XY; Liang XN; Jiao FY; Ge JJ; Wu P; Li G; Shen B; Wu B; Sun YM; Zhu YH; Luo JF; Yen TC; Wu JJ; Zuo CT; Wang J;
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1395-1405. PubMed ID: 36627498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.